Cataract Surgery with Alcon’s AcrySof IQ Vivity IOLs Demonstrates Sustained High Patient Satisfaction and Reduced Spectacle Dependence

Alcon Vivity Registry continues to demonstrate excellent outcomes with AcrySof IQ Vivity and AcrySof IQ Vivity Toric, the first and only PCIOL+ with wavefront-shaping technology
World-renowned surgeons will present new registry data at #ESCRS2023, including data on rates of visual disturbances1,2
Registry monitored 900+ cataract patients post-surgery, including those with certain mild comorbidities

September 09, 2023 01:01 AM Eastern Daylight Time

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today revealed final data from its Vivity® Registry Study, which monitored real-world patient experiences for up to 12 months post cataract surgery with implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens (PCIOL). Data from more than 900 cataract patients demonstrated sustained clinical performance, high patient satisfaction and reduced dependence upon spectacles (glasses). Evidence also suggested that AcrySof® IQ Vivity® can be used successfully in a broad range of patients, providing surgeons and patients with additional treatment options.